Status:
COMPLETED
Alpha MSH in Ocular Disease
Lead Sponsor:
Duke University
Conditions:
Advanced Dry Macular Degeneration
Eligibility:
All Genders
60+ years
Phase:
NA
Brief Summary
The purpose of this study is gain a better understanding of a molecule called alpha melanocyte stimulating hormone (alpha MSH) and its potential role in your retinal disease. Alpha MSH has been shown ...
Detailed Description
A small amount (0.1 mL) of aqueous humor would be removed from the study eye in the clinic setting. This sample will be processed and then sent off for measurement of alpha MSH levels.
Eligibility Criteria
Inclusion
- 60 years or older
- diagnosis of advanced dry macular degeneration with foveal geographic atrophy
- limited vision or blindness (20/100 or worse) in that eye
- pseudophakia (prior cataract surgery in that eye)
Exclusion
Key Trial Info
Start Date :
March 6 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 19 2021
Estimated Enrollment :
54 Patients enrolled
Trial Details
Trial ID
NCT03451578
Start Date
March 6 2018
End Date
October 19 2021
Last Update
December 22 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Duke University Eye Center
Durham, North Carolina, United States, 27710